Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Lyell Immunopharma, Inc. President and CEO Lynn Seely reported a small stock transaction related to taxes on equity compensation. On May 11, 2026, 388 shares of common stock were sold at a weighted average price of $18.91 per share to cover a tax withholding obligation from the settlement of vested restricted stock units. After this tax-related sale, Seely directly holds 73,878 shares of Lyell Immunopharma common stock, indicating that the transaction affects only a very small portion of her overall holdings and reflects a routine administrative disposition rather than a discretionary portfolio change.
Lyell Immunopharma, Inc. Chief Scientific Officer Gary K. Lee reported an automatic share sale tied to tax withholding. On May 11, 2026, 130 shares of common stock were sold at a weighted average price of $18.92 per share to cover tax obligations from the settlement of vested restricted stock units.
After this transaction, Lee directly held 17,808 shares of Lyell Immunopharma common stock. This total includes 1,000 shares acquired on May 18, 2026 under the company’s 2021 Employee Stock Purchase Plan, indicating that the filing reflects both routine compensation-related activity and associated tax withholding.
Lyell Immunopharma, Inc. Chief Operating Officer Stephen J. Hill reported an automatic sale of 89 shares of common stock on May 11, 2026 at a weighted average price of $18.92 per share. The shares were sold to cover tax withholding obligations from the settlement of vested restricted stock units. After this tax-related sale, Hill directly held 17,894 shares of Lyell Immunopharma common stock.
Lyell Immunopharma, Inc. VP and Corporate Controller Veronica Sanchez Bulis reported a small open-market sale of company common stock. She sold 217 shares on May 11, 2026, automatically to cover a tax withholding obligation from the settlement of vested restricted stock units.
The shares were sold at a weighted average price between $18.91 and $19.30 per share. After this tax-related sale, she directly owns 15,420 shares of Lyell Immunopharma common stock.
Lyell Immunopharma, Inc. reported the voting results from its 2026 annual meeting of stockholders. A quorum was established, with 15,706,826 shares represented, equal to 67.31% of the 23,332,254 shares outstanding as of April 14, 2026.
Stockholders elected Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin to the board, each receiving more than 11.8 million votes in favor. Stockholders also approved a proposal with 15,674,347 votes for and 30,758 against, and an additional proposal received 11,860,218 votes for and 3,429,286 broker non-votes.
Lyell Immunopharma director William JL Rieflin received a new stock option grant for 9,250 shares of common stock. The option has an exercise price of $13.22 per share and expires on June 9, 2036.
According to the award terms, these option shares vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that meeting if his board service ends at that time) or the first anniversary of June 10, 2026, provided he continues serving through the vesting date. After this grant, his reported option holdings from this award total 9,250 shares.
Lyell Immunopharma director Sumant Ramachandra reported an equity award and updated holdings. He received an option grant covering 9,250 shares of common stock at an exercise price of $13.22 per share, expiring on June 9, 2036.
The option vests on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if his board service ends at that meeting) or the first anniversary of that date, contingent on continuous service. In addition, 10,000 shares of common stock are held indirectly by the Sumant Ramachandra Rev Trust DTD 01/24/12, where he is grantor and trustee. All share amounts reflect a 1-for-20 reverse stock split effected on May 30, 2025.
Lyell Immunopharma director Elizabeth G. Nabel received a grant of stock options covering 9,250 shares of common stock. The options have an exercise price of $13.22 per share and were awarded as a compensation grant, not an open-market purchase or sale.
The options vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting), or the first anniversary of June 10, 2026, provided she continues serving as a director. The options expire on June 9, 2036, and following this grant she holds options to acquire 9,250 shares.
Lyell Immunopharma director Richard Klausner received a grant of 9,250 stock options for common stock, each with a $13.22 exercise price and expiring on June 9, 2036. This is a compensation-related award rather than an open-market purchase.
The options will vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if he leaves the board at that meeting) or the first anniversary of that date, assuming continuous service. Following the reporting date, he held 148,391 common shares directly and 42,166 shares indirectly through family and Delaware trusts, with beneficial ownership of the Delaware trusts disclaimed except for any pecuniary interest. All share amounts reflect a 1-for-20 reverse stock split effective May 30, 2025.
Lyell Immunopharma director Cathy Friedman received a compensatory stock option grant for 9,250 shares of common stock. The option has an exercise price of $13.22 per share and expires on June 9, 2036. All share amounts reflect Lyell’s 1-for-20 reverse stock split effective May 30, 2025.
The option will vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting) or the first anniversary of June 10, 2026, subject to her continuous service. The filing also reports 5,000 shares held by The Duane Irrevocable Trust 2020 and 11,818 shares held by the Duane Family Trust, where Friedman is a trustee and disclaims beneficial ownership except to any pecuniary interest.